Veracyte Inc. (VCYT)
NASDAQ: VCYTHealth CareMedical SpecialitiesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 42.91 -0.58%
VCYT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.47B
- P/E (TTM)
- 31.97
- Forward P/E
- 22.13
- EPS (TTM)
- $1.35
- Dividend yield
- None
- 52-week range
- 29.46 – 60.91
- Day range
- 42.34 – 44.21
- Volume / Avg
- 1.21M / 1.35M
- Beta
- —
- Shares outstanding
- 80.39M
- Next earnings
- Nov 3, 2026
52-week range
VCYT stock today
On Oct 7, VCYT ended the session at $43.16, shedding $1.49 (3.34%), versus the S&P 500's 0.22% decline. At this level, VCYT sits in the middle of its 52-week range of $29.46 to $60.91: 29.1% below the high, set on Jun 30, 2026 and 46.5% above the low. VCYT is up 2.5% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 24.7%.
At 32.0x trailing earnings, Veracyte trades in line with the peer-group median of 30.6x. Its forward P/E of 22.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Veracyte's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Veracyte
Company profileVeracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. Marc A. Stapley
- Headquarters
- South San Francisco, CA
- Employees
- 755
- IPO year
- 2013
- Website
- veracyte.com
Financial highlights
Full financialsIn fiscal 2025, Veracyte generated $517.1 million in revenue, up 16.0% from fiscal 2024, its 5th consecutive year of revenue growth. Net income was $66.4 million (+174.9% year over year), for a net margin of 12.8% versus a median of -20.6% in the prior 5 years. Gross margin was 70.1% (up from 66.9%) and operating margin 11.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $517.14M | $445.76M | $361.05M | $296.54M | $219.51M |
| Growth | +16.01% | +23.46% | +21.76% | +35.09% | +86.85% |
| Net income | $66.35M | $24.14M | $-74.40M | $-36.56M | $-75.56M |
| EPS (diluted) | $0.82 | $0.31 | $-1.02 | $-0.51 | $-1.11 |
Analyst forecast
ForecastConsensus (13 analysts)
buy
Avg. price target
$58.42+35.36%
- Strong buy 2
- Buy 9
- Hold 1
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $0.28
- Last reported (Q2 2026)
- Jul 31, 2026
- EPS actual vs est.
- $0.31 vs —
VCYT news
All VCYT news- Veeva's DQS Scales Data Automation Across 1,000+ Clinical StudiesNasdaqVEEV, WST, GMED, VCYT
- Is This the Right Time to Add TMO Stock to Your Portfolio?NasdaqTMO, GMED, PAHC, VCYT
- Veeva's OpenData to Help Servier Build a Global AI Data FoundationNasdaqVEEV, WST, GMED, VCYT
- 10x Genomics Begins Atera Shipments as Spatial Biology Demand RisesNasdaqTXG, ISRG, GMED, VCYT
- Here's Why You Should Retain McKesson Stock in Your Portfolio for NowNasdaqMCK, ISRG, GMED, VCYT
- Here's Why You Should Retain Revvity Stock in Your Portfolio for NowNasdaqRVTY, ISRG, GMED, VCYT
- Fresenius Medical Care Reshapes China Portfolio for Long-Term GrowthNasdaqFMS, ISRG, GMED, VCYT
- Here's Why You Should Retain BDX Stock in Your Portfolio for NowNasdaqBDX, WST, GMED, VCYT
Veracyte peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CDNACareDx Inc. | 63.04 | -1.18% | $3.26B | vs VCYT |
| CELCCelcuity Inc. | 65.78 | -7.68% | $3.22B | vs VCYT |
| ACHCAcadia Healthcare Company Inc. | 29.23 | +0.65% | $2.72B | vs VCYT |
| BLLNBillionToOne Inc. Class A | 95.75 | -4.19% | $4.52B | vs VCYT |
| CONConcentra Group Holdings Parent Inc. | 36.40 | 0.00% | $4.64B | vs VCYT |
| FTREFortrea Holdings Inc. | 20.56 | -1.06% | $1.96B | vs VCYT |
| PSNLPersonalis Inc. | 16.00 | -0.19% | $1.71B | vs VCYT |
| RDNTRadNet Inc. | 68.61 | -2.38% | $5.40B | vs VCYT |
Indexes, lists and sector
Veracyte stock FAQ
What is Veracyte's stock price today?
VCYT last traded at $43.16 as of Oct 7, 4:00 PM EDT, down 3.34% on the day. Prices are delayed at least 15 minutes.
When is Veracyte's next earnings date?
Veracyte is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $0.28.
What is VCYT's P/E ratio?
VCYT trades at a trailing P/E ratio of 31.97 and a forward P/E of 22.13, compared with a median of 30.6 for its closest peers.
Who is Veracyte's CEO?
Mr. Marc A. Stapley is the chief executive officer of Veracyte Inc., which has about 755 employees.
What is the VCYT 52-week high?
The 52-week high for VCYT is $60.91 and the 52-week low is $29.46. The stock is currently 29.1% below its high.